Quantum Biopharma (QNTM) Stock Price, News & Analysis

Company Overview

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $5.15 to $5.59
• 50-Day Range: $2.10 to $5.73
• 52-Week Range: $2.07 to $38.25
• Volume: 244,056 shs
• Average Volume: 426,186 shs
• Market Capitalization: $20.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Quantum Biopharma Stock Analysis - MarketRank™

Quantum Biopharma scored higher than 12% of companies evaluated by MarketBeat, and ranked 812th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Quantum Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Quantum Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Quantum Biopharma is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quantum Biopharma is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Quantum Biopharma has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.18% of the float of Quantum Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Quantum Biopharma has a short interest ratio ("days to cover") of 0.54, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quantum Biopharma has recently decreased by 27.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quantum Biopharma does not currently pay a dividend.

Dividend Growth

Quantum Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Quantum Biopharma has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Quantum Biopharma this week, compared to 3 articles on an average week.

Search Interest

15 people have searched for QNTM on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

12 people have added Quantum Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quantum Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.53% of the stock of Quantum Biopharma is held by insiders.

Percentage Held by Institutions

1.24% of the stock of Quantum Biopharma is held by institutions.

QNTM Stock Analysis - Frequently Asked Questions

How have QNTM shares performed this year?

Quantum Biopharma's stock was trading at $7.30 at the beginning of 2026. Since then, QNTM stock has decreased by 26.6% and is now trading at $5.36.

How were Quantum Biopharma's earnings last quarter?

Quantum Biopharma Ltd. (NASDAQ:QNTM) posted its earnings results on Thursday, March, 26th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.49.

Who are Quantum Biopharma's major shareholders?

Quantum Biopharma's top institutional investors include Platform Technology Partners (1.08%).

How do I buy shares of Quantum Biopharma?

Shares of QNTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Quantum Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quantum Biopharma investors own include Jiuzi (JZXN), Aethlon Medical (AEMD), Aditxt (ADTX), Adial Pharmaceuticals (ADIL), Avalon GloboCare (ALBT), Ainos (AIMD) and AMC Entertainment (AMC).

Company Calendar

• Last Earnings: 3/26/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QNTM
• Previous Symbol: NASDAQ:QNTM
• CIK: 1771885
• Web: www.fsdpharma.com
• Phone: 416-854-8884
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($8.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -436.23%
• Return on Assets: -150.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.07
• Quick Ratio: 1.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.34 per share
• Price / Book: 4.00

Miscellaneous

• Outstanding Shares: 3,820,000
• Free Float: 3,491,000
• Market Cap: $20.48 million
• Optionable: N/A
• Beta: 0.29